All > Paid Studies Dallas

HPN536 for Mesothelin-Associated Cancers

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Mesothelin-Associated CancersHPN536 - Biological
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing a new drug, HPN536, to see if it is safe and effective in treating advanced cancers associated with mesothelin expression.

Eligible Conditions
  • Mesothelin-Associated Cancers

Treatment Effectiveness

Effectiveness Progress

1 of 3

Similar Trials

1
Getting Ahead in a Just-Gettin'-By World
1
Active Dronabinol
1
Simvastatin

Study Objectives

4 Primary · 0 Secondary · Reporting Duration: 3 years

1 year
Efficacy of HPN536 at the recommended Phase 2 dose: overall response rate (ORR)
2 years
Determine MTD/RP2D
3 years
Assessment of Adverse Events by CTCAE 5.0 of HPN536
Day 21
Assess initial safety and determination of recommended Phase 2 dose: Dose limiting toxicity

Trial Safety

Safety Progress

1 of 3

Similar Trials

1
Getting Ahead in a Just-Gettin'-By World
1
Active Dronabinol
1
Simvastatin

Trial Design

2 Treatment Groups

HPN536-2001 - Part 1 (Dose Escalation)
1 of 2
HPN536-2001 - Part 2 (Dose Expansion)
1 of 2

Experimental Treatment

200 Total Participants · 2 Treatment Groups

Primary Treatment: HPN536 · No Placebo Group · Phase 1 & 2

HPN536-2001 - Part 1 (Dose Escalation)
Biological
Experimental Group · 1 Intervention: HPN536 · Intervention Types: Biological
HPN536-2001 - Part 2 (Dose Expansion)
Biological
Experimental Group · 1 Intervention: HPN536 · Intervention Types: Biological

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 3 years

Who is running the clinical trial?

Harpoon TherapeuticsLead Sponsor
3 Previous Clinical Trials
167 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You have malignant mesothelioma with epithelioid histology, pleural or peritoneal type.
A tissue sample is required for enrollment.
You have an absolute neutrophil count (ANC) of 1500/mm3 or more.
Platelets ≥100,000/mm3 or ≥100 x 109/L.
You have adequate renal function, including estimated creatinine clearance ≥30 mL/min.
References

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top